Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Mar;63(3):399–403. doi: 10.1038/bjc.1991.92

Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSF.

S T Malik 1, D Martin 1, I Hart 1, F Balkwill 1
PMCID: PMC1971867  PMID: 2003980

Abstract

Three intraperitoneal human ovarian cancer xenografts (OS, HU, and LA) were used to assess the antitumour activity of intraperitoneal therapy with liposome encapsulated MTP-PE. MTP-PE led to significant prolongation of survival in all three xenograft models, but with varying efficacy. In one tumour model (OS), 80% of mice were cured of tumour by twice weekly therapy for 4 weeks, whereas in another xenograft model (LA), the median survival time was approximately doubled compared to PBS injected and placebo liposome injected controls (median survivals: 30 vs 62.5 days respectively). The antitumor efficacy of MTP-PE did not correlate with the extent of peritoneal neutrophil infiltration after intraperitoneal therapy. Combined therapy with liposome encapsulated MTP-PE and recombinant murine granulocyte-macrophage colony stimulating factor led to increased survival of mice bearing the LA and HU xenografts, compared to tumour bearing mice treated with either agent singly.

Full text

PDF
399

Images in this article

401Figure 2
on p.401

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Broudy V. C., Kaushansky K., Shoemaker S. G., Aggarwal B. B., Adamson J. W. Muramyl dipeptide induces production of hemopoietic growth factors in vivo by a mechanism independent of tumor necrosis factor. J Immunol. 1990 May 15;144(10):3789–3794. [PubMed] [Google Scholar]
  2. Espevik T., Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods. 1986 Dec 4;95(1):99–105. doi: 10.1016/0022-1759(86)90322-4. [DOI] [PubMed] [Google Scholar]
  3. Fidler I. J., Fogler W. E., Brownbill A. F., Schumann G. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide. J Immunol. 1987 Jun 15;138(12):4509–4514. [PubMed] [Google Scholar]
  4. Grabstein K. H., Urdal D. L., Tushinski R. J., Mochizuki D. Y., Price V. L., Cantrell M. A., Gillis S., Conlon P. J. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science. 1986 Apr 25;232(4749):506–508. doi: 10.1126/science.3083507. [DOI] [PubMed] [Google Scholar]
  5. Hsu S. M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981 Apr;29(4):577–580. doi: 10.1177/29.4.6166661. [DOI] [PubMed] [Google Scholar]
  6. Lichtenstein A. K., Kahle J., Berek J., Zighelboim J. Successful immunotherapy with intraperitoneal Corynebacterium parvum in a murine ovarian cancer model is associated with the recruitment of tumor-lytic neutrophils into the peritoneal cavity. J Immunol. 1984 Jul;133(1):519–526. [PubMed] [Google Scholar]
  7. Lichtenstein A., Seelig M., Berek J., Zighelboim J. Human neutrophil-mediated lysis of ovarian cancer cells. Blood. 1989 Aug 1;74(2):805–809. [PubMed] [Google Scholar]
  8. Malik S. T., Griffin D. B., Fiers W., Balkwill F. R. Paradoxical effects of tumour necrosis factor in experimental ovarian cancer. Int J Cancer. 1989 Nov 15;44(5):918–925. doi: 10.1002/ijc.2910440529. [DOI] [PubMed] [Google Scholar]
  9. Manetta A., Podczaski E., Zaino R. J., Satyaswaroop P. G. Therapeutic effect of recombinant human tumor necrosis factor in ovarian carcinoma xenograft in nude mice. Gynecol Oncol. 1989 Sep;34(3):360–364. doi: 10.1016/0090-8258(89)90174-1. [DOI] [PubMed] [Google Scholar]
  10. Ortaldo J. R., Porter H. R., Miller P., Stevenson H. C., Ozols R. F., Hamilton T. C. Adoptive cellular immunotherapy of human ovarian carcinoma xenografts in nude mice. Cancer Res. 1986 Sep;46(9):4414–4419. [PubMed] [Google Scholar]
  11. Phillips N. C., Moras M. L., Chedid L., Lefrancier P., Bernard J. M. Activation of alveolar macrophage tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative. Cancer Res. 1985 Jan;45(1):128–134. [PubMed] [Google Scholar]
  12. Sayers T. J., Wiltrout T. A., Bull C. A., Denn A. C., 3rd, Pilaro A. M., Lokesh B. Effect of cytokines on polymorphonuclear neutrophil infiltration in the mouse. Prostaglandin- and leukotriene-independent induction of infiltration by IL-1 and tumor necrosis factor. J Immunol. 1988 Sep 1;141(5):1670–1677. [PubMed] [Google Scholar]
  13. Sone S., Fidler I. J. Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages. J Immunol. 1980 Dec;125(6):2454–2460. [PubMed] [Google Scholar]
  14. Sone S., Lopez-Berestein G., Fidler I. J. Potentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivatives. Cancer Immunol Immunother. 1986;21(2):93–99. doi: 10.1007/BF00199855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sone S., Utsugi T., Tandon P., Ogawara M. A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state. Cancer Immunol Immunother. 1986;22(3):191–196. doi: 10.1007/BF00200032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Talmadge J. E., Lenz B. F., Klabansky R., Simon R., Riggs C., Guo S., Oldham R. K., Fidler I. J. Therapy of autochthonous skin cancers in mice with intravenously injected liposomes containing muramyltripeptide. Cancer Res. 1986 Mar;46(3):1160–1163. [PubMed] [Google Scholar]
  17. Talmadge J. E., Schneider M., Collins M., Phillips H., Herberman R. B., Wiltrout R. H. Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE. J Immunol. 1985 Aug;135(2):1477–1483. [PubMed] [Google Scholar]
  18. Ward B. G., Wallace K., Shepherd J. H., Balkwill F. R. Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice. Cancer Res. 1987 May 15;47(10):2662–2667. [PubMed] [Google Scholar]
  19. Xu Z., Fidler I. J. The in situ activation of cytotoxic properties in murine Kupffer cells by the systemic administration of whole Mycobacterium bovis organisms or muramyl tripeptide. Cancer Immunol Immunother. 1984;18(2):118–122. doi: 10.1007/BF00205745. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES